ArticleAnnals of medicine and surgery (2012)2025
Directly acting antivirals improve insulin resistance in nondiabetic patients with hepatitis C: a systematic review and meta-analysis.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hepatitis C Virus: An Overview of Its Chronic Impact on Liver Function, Metabolic Dysregulation, Inflammatory-Oxidative Pathogenesis and Epigenetic Memory.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Insulin resistance, beta-cell dysfunction, and diabetes mellitus (DM) are the extrahepatic complications of chronic hepatitis C virus (HCV) infection. The aim of the study was to determine the effects of novel directly acting antivirals (DAAs) on insulin resistance and insulin sensitivity parameters in nondiabetic patients with chronic HCV infection. Methods: A systematic search of medical databases (Pubmed, Scopus, and Google Scholar) was conducted for studies published until July 2024. Studies investigating the effect of any DAA on insulin resistance and insulin sensitivity parameters in non-diabetic patients with chronic HCV and sustained virologic response were included. Our study assessed the Homeostasis Model Assessment for Insulin Resistance (HOMA-IR) as the primary outcome. The pooled outcomes were compared pretreatment and posttreatment with DAAs using Hedges' g (HG) with a 95% confidence interval (CI). Results: A total of 10 studies (1309 participants) were included in the meta-analysis. Insulin resistance measured by the HOMA-IR was significantly reduced with DAA therapy (HG = 0.86, 95% CI: 0.48-1.25, Conclusions: The use of DAAs in nondiabetic chronic HCV patients with a sustained virologic response also significantly reduces insulin resistance and fasting insulin levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.